Overcoming Innate Immune Barriers that Impede AAV Gene Therapy Vectors

Time: 3:30 pm
day: Day Two

Details:

  • What is known about innate immune responses in AAV-based gene therapy?
  • Understand the role of complement in AAV immunogenicity
  • Potential immunomodulatory strategies to circumvent AAV related immune responses
  • Despite the recent clinical successes achieved with AAVs for therapeutics, host innate immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies
  • These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines
  • Assess the role of the innate immune system on the vector and its role in priming the adaptive immune system to attack said vector

Speakers: